For pancreatic cancer, LRRC8A inhibition presents the intriguing possibility of converting an immunosuppressive microenvironment to an immunopermissive one, potentially synergizing with checkpoint inhibitor immunotherapies. Here, LRRC8A is linked to pancreatic neoplasm.